Comparison of Levofloxacin based quadruple therapy with standard treatment in eradication of helicobacter pylori as first line Therapy

Comparison of Levofloxacin-containing quadruple therapy versus standard triple therapy as the first line for the helicobacter pylori eradication

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171112037420N1

Enrollment

Registered

2018-01-03

Start date

2017-06-13

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter Pylori infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Control group: Levofloxacin-containing quadruple therapy (Levofloxacin 500 mg bid, Bismuth 240 mg qid, Amoxicillin 1 gr bid and Pantoprazole 40 mg bid) for 2 weeks. Intervention 2: In

Treatment - Drugs

Control group: Levofloxacin-containing quadruple therapy (Levofloxacin 500 mg bid, Bismuth 240 mg qid, Amoxicillin 1 gr bid and Pantoprazole 40 mg bid) for 2 weeks

Intervention group: standard triple therapy (Clarithromycin 500 mg bid, Amoxicillin 1 gr bid, Pantoprazole 40 mg bid) for 2 weeks

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients who are performed upper endoscopy and have positive rapid urease test. Patients with over 18 years of age

Exclusion criteria

Exclusion criteria: Pregnancy Allergy to medicent which used this study Patients were treated helicobacter pylori eradication previously. lack of willingness to continue the period of treatment lack of willingness to complete the period of treatment

Design outcomes

Primary

Measure	Time frame
Eradication of Helicobacter Pylori infection. Timepoint: 3 weeks after the completion of treatment. Method of measurement: Helicobacter pylori stool antigen test.	—

Secondary

Measure	Time frame
Diarrhea. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Nausea. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Headache. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Hiccups. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Skin rash. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Papilation. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Bitter taste. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Neuropathic pain. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Constipation. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Chest stress. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Vometting. Timepoint: During the period of treatment. Method of measurement: Questionnaire.	—

Measure

Time frame

Diarrhea. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Nausea. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Headache. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Hiccups. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Skin rash. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Papilation. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Bitter taste. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Neuropathic pain. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Constipation. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Chest stress. Timepoint: During the period of treatment. Method of measurement: Questionnaire.;Vometting. Timepoint: During the period of treatment. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactM.s Salehe Eydi

Sabzevar University of Medical Sciences

info@medsab.ac.ir+98 51 4401 1000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026